Jazz Pharmaceuticals

Jazz's Ziihera Beats Trastuzumab on Survival in Phase 3 GEA Trial

September 03, 2026 – Dublin -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that Ziihera (zanidatamab-hrii) plus chemotherapy achieved a statistically significant and clinically meaningful overall survival benefit over trastuzumab plus chemotherapy in first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma (GEA), based on a second interim analysis of the Phase 3 HERIZON-GEA-01 trial.

Ziihera's survival hazard ratio improved from the first interim analysis

The Ziihera plus chemotherapy arm showed an improved OS hazard ratio compared with the trial's first interim readout, according to Jazz. The company said the safety profile remained consistent with prior HERIZON-GEA-01 data and each agent's known profile, with no new safety signals identified.

Jazz's Ziihera Shows Significant Survival Edge Over Trastuzumab in GEA Trial

September 03, 2026 – Dublin -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that Ziihera (zanidatamab-hrii) combined with chemotherapy produced a statistically significant and clinically meaningful overall survival (OS) benefit versus trastuzumab plus chemotherapy in a second interim analysis of the Phase 3 HERIZON-GEA-01 trial in first-line HER2-positive gastroesophageal adenocarcinoma (GEA).

OS hazard ratio for Ziihera plus chemotherapy improved versus the first interim analysis

The company said the survival advantage strengthened compared with earlier data, reinforcing Ziihera's position following its FDA approval on August 25, 2026. No new safety signals emerged relative to previously reported HERIZON-GEA-01 data or the known profiles of the individual agents.